Plasma protein binding

DGAP-News: Tetra Bio-Pharma Receives Positive Opinion for Orphan Drug Designation for QIXLEEF(TM) from the European Medicines Agency

Thursday, October 21, 2021 - 12:09pm

An ODD brings several unique advantages, from a cost reduction in drug development, to an accelerated review process and market exclusivity for 10 years.

Key Points: 
  • An ODD brings several unique advantages, from a cost reduction in drug development, to an accelerated review process and market exclusivity for 10 years.
  • Such strategy is cost and time effective and allows the Company to easily gain market shares in a competitive free environment.
  • We firmly believe that QIXLEEF(TM) will be a safe and effective medicine for pain management and an alternative to opioids."
  • The positive opinion issued by the COMP will be sent to the European Commission, which is expected to grant the orphan designation within 30 days.

Tetra Bio-Pharma Receives Positive Opinion for Orphan Drug Designation for QIXLEEF™ from the European Medicines Agency

Thursday, October 21, 2021 - 11:30am

Guy Chamberland, Chief Executive Officer and Chief Regulatory Officer of Tetra Bio-Pharma said "the positive opinion issued by the COMP is excellent news as Tetra continues to execute its regulatory strategy in Europe.

Key Points: 
  • Guy Chamberland, Chief Executive Officer and Chief Regulatory Officer of Tetra Bio-Pharma said "the positive opinion issued by the COMP is excellent news as Tetra continues to execute its regulatory strategy in Europe.
  • We firmly believe that QIXLEEF will be a safe and effective medicine for pain management and an alternative to opioids."
  • The positive opinion issued by the COMP will be sent to the European Commission, which is expected to grant the orphan designation within 30 days.
  • The COMP based on majority of 30 out of 31 votes concluded that QIXLEEF satisfies the criteria for such designation and recommends the granting of orphan medicinal product designation.

Healthera Launches "Treatments", enabling app-based access to Erectile Dysfunction medicines from Local Pharmacies

Thursday, October 21, 2021 - 8:00am

Instead, patients will be able to fill out a questionnaire within the Healthera app that their pharmacist will review and approve if appropriate.

Key Points: 
  • Instead, patients will be able to fill out a questionnaire within the Healthera app that their pharmacist will review and approve if appropriate.
  • Treatments sits alongside Healthera's existing platform for repeat prescription delivery, OTC eCommerce, and on-demand service booking offered by local pharmacies, for a complete patient experience.
  • Additional treatments will be released periodically, starting with Erectile Dysfunction (ED), where commonly bought medication such as Viagra Connect will be made available.
  • We're excited to see this service roll out and grow as we continue bringing even more treatments online in the coming months."

Healthera Launches "Treatments", enabling app-based access to Erectile Dysfunction medicines from Local Pharmacies

Thursday, October 21, 2021 - 8:00am

CAMBRIDGE, England, Oct. 21, 2021 /PRNewswire/ -- Today Healthera introduces an additional Treatments functionality to its digital platform. This allows its pharmacy partners to remotely sell medication that previously required face to face consultations. Instead, patients will be able to fill out a questionnaire within the Healthera app that their pharmacist will review and approve if appropriate.

Key Points: 
  • Instead, patients will be able to fill out a questionnaire within the Healthera app that their pharmacist will review and approve if appropriate.
  • Treatments sits alongside Healthera's existing platform for repeat prescription delivery, OTC eCommerce, and on-demand service booking offered by local pharmacies, for a complete patient experience.
  • Additional treatments will be released periodically, starting with Erectile Dysfunction (ED), where commonly bought medication such as Viagra Connect will be made available.
  • We're excited to see this service roll out and grow as we continue bringing even more treatments online in the coming months."

Online Canadian Pharmacies Benefitting Americans Without Insurance

Thursday, October 21, 2021 - 12:00am

Many of the drugs needed to manage diabetes, hypertension, hypothyroidism and other conditions are expensive, but an online Canadian pharmacy like Canada Pharmacy can provide the savings people need.

Key Points: 
  • Many of the drugs needed to manage diabetes, hypertension, hypothyroidism and other conditions are expensive, but an online Canadian pharmacy like Canada Pharmacy can provide the savings people need.
  • There is more to it than that, but the only big-picture understanding that many Americans - ones with OR without health insurance - may want to know is they can pay less for drugs, and if ordering from online Canadian pharmacies is the best way to do that.
  • Americans without health insurance are encouraged to look into what they would pay ordering their medication from Canada.
  • Canada Pharmacy is a Canadian online pharmacy among those recommended for Americans who shop at a pharmacy in Canada to save money on medications.

Global Ophthalmic Drugs Market (2021 to 2029) - Featuring Abbott Healthcare, Allergan and Bayer Among Others - ResearchAndMarkets.com

Wednesday, October 20, 2021 - 6:05pm

Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global ophthalmic drugs market.

Key Points: 
  • Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global ophthalmic drugs market.
  • Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global ophthalmic drugs market.
  • This report concludes with company profiles section that highlights major information about the key players engaged in ophthalmic drugs market.
  • The ophthalmic drug industry can be classified into prescription ophthalmic drugs and over the counter (OTC) drugs.

Common Citizen to offer low-cost or free cannabis to low-income patients, those with severe or terminal illnesses

Wednesday, October 20, 2021 - 5:01pm

Details of the program will be announced in late November with plans to launch the program in early 2022.

Key Points: 
  • Details of the program will be announced in late November with plans to launch the program in early 2022.
  • With the rising costs of prescription drugs, it has never been more important for our patients who rely on our safe, high-quality cannabis products to have access to their medicine, Common Citizen CEO Michael Elias said.
  • Common Care will help us achieve Cannabis for Humanity, and that includes serving the unique, individual needs of all our patients across Michigan.
  • Launched in Detroit in 2018, the Common Citizen brand takes a deliberate, people-first approach to its business strategy from production to retail.

Citeline Connect Clinical Trial Recruitment Platform Announces Expansion of Reach into all Global Markets

Wednesday, October 20, 2021 - 5:00pm

Based on our overwhelming success recruiting for US-based trial sites, combined with the increased need for trial participants at sites outside the US, we saw an opportunity for Citeline Connect to help more study sponsors meet enrollment goals, said Chris Venezia, Chief Commercial Officer at Citeline Connect.

Key Points: 
  • Based on our overwhelming success recruiting for US-based trial sites, combined with the increased need for trial participants at sites outside the US, we saw an opportunity for Citeline Connect to help more study sponsors meet enrollment goals, said Chris Venezia, Chief Commercial Officer at Citeline Connect.
  • Our robust prescreening process minimizes screen fails, enabling sponsors to recruit faster and more efficiently than ever before.
  • With more than 400 analysts keeping their fingers on the pulse of the industry, no key disease, clinical trial, drug approval or R&D project isnt covered through the breadth and depth of data available to customers.
  • For more information, visit pharmaintelligence.informa.com .

Report from Incubate Policy Lab and Charles River Associates Finds Congressional Budget Office Underestimates Negative Impact of Drug Pricing Legislation

Wednesday, October 20, 2021 - 3:09pm

3, would have a far greater negative impact than estimated by the Congressional Budget Office.

Key Points: 
  • 3, would have a far greater negative impact than estimated by the Congressional Budget Office.
  • "Our new report captures what the Congressional Budget Office failed to incorporate: investor behavior.
  • The advocacy organization recently launched its research arm, Incubate Policy Lab, which explores various policy initiatives and potential effects on the biopharmaceutical industry.
  • AboutCharles River Associates: Charles River Associates is a leading global consulting firm specializing ineconomic, financial, and management consulting services.

Advisory - Ivermectin not authorized to prevent or treat COVID-19; may cause serious health problems

Tuesday, October 19, 2021 - 11:36pm

Health Canada is reminding Canadians not to use ivermectin to prevent or treat COVID-19.

Key Points: 
  • Health Canada is reminding Canadians not to use ivermectin to prevent or treat COVID-19.
  • There is no evidence that ivermectin works to prevent or treat COVID-19, and it is not authorized for this use.
  • Health Canada has received concerning reports of the use of veterinary ivermectin to prevent or treat COVID-19.
  • In this light, Health Canada is advising Canadians not to use either the veterinary or human drug versions of ivermectin to prevent or treat COVID-19.